Skip to main content
Multiple Sclerosis Discovery Forum
Inspiring Connections
Utility Navigation
Feedback
Newsletter
RSS
Twitter
User Top Menu
Welcome, guest
Log In
Join
Why Join?
Search form
Search
About Us
Overview
Who We Are
Contact
Fan Mail
How to Cite
News & Future Directions
New Findings
News Briefs
Podcasts
News Synthesis
Essays & Opinions
Blogs
Papers
Editors' Picks
Classic Papers
Archive
Forums
Discussions
Webinars
Professional Resources
Meetings & Events
Past Meetings
Funding Opportunities
Jobs
Member Directory
Bulletin Board
Useful Links
Research Resources
Data Visualizations
Clinical Trials - Public Availability of Results
World Map
MS trials baseline
NMO History
NMO Galaxy
Map of MS Prevalence
Progressive MS Authors Galaxy
Word Cloud
MSLine
Ongoing Clinical Trials in MS
MRI-Related Clinical Trials
RRMS and CIS
Immunopathogenesis of MS
The MS Galaxy
ARR in Placebo Groups
Symptoms Prevalence
Scientific Literature TreeMap
Clinical Trials in MS
Drug-Development Pipeline
Tissue Repositories
MSGene
Animal Models
Clinical Trials
Click Here to Support MSDF
You are here
Home
Most Viewed Papers
FDA product review for daclizumab
'Clinically definite benign multiple sclerosis', an unwarranted conceptual hodgepodge: evidence from a 30-year observational study.
How integrated are neurology and palliative care services? Results of a multicentre mapping exercise.
Synergistic Effects of Reserve and Adaptive Personality in Multiple Sclerosis.
CNS vasculitis in a patient with MS on daclizumab monotherapy.
The budget impact of introducing delayed-release dimethyl fumarate for treatment of relapse-remitting multiple sclerosis in Canada.
Proinflammatory GM-CSF-producing B cells in multiple sclerosis and B cell depletion therapy.
Safety and tolerability of daclizumab HYP treatment in relapsing-remitting multiple sclerosis: results of the DECIDE study
Revised Recommendations of the Consortium of MS Centers Task Force for a Standardized MRI Protocol and Clinical Guidelines for the Diagnosis and Follow-Up of Multiple Sclerosis.
Disseminated zoster with paresis in a multiple sclerosis patient treated with dimethyl fumarate.
Postpartum relapses increase the risk of disability progression in multiple sclerosis: the role of disease modifying drugs.
Reduction of CD8(+) T lymphocytes in multiple sclerosis patients treated with dimethyl fumarate.
Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group.
Biomarkers of disease activity in multiple sclerosis.
Quantifying brain volumes for Multiple Sclerosis patients follow-up in clinical practice - comparison of 1.5 and 3 Tesla magnetic resonance imaging.
Ampyra (Fampyra)
Dimethyl fumarate regulates histone deacetylase expression in astrocytes.
Maternal and perinatal outcomes in pregnancies with multiple sclerosis: a case-control study.
Circulating miR-150 in CSF is a novel candidate biomarker for multiple sclerosis.
Cognitive Impairment in Multiple Sclerosis: Clinical Manifestation, Neuroimaging Correlates, and Treatment.
Clinical proteomics of enervated neurons.
Mechanism of action for leflunomide in rheumatoid arthritis.
Dimethyl fumarate (BG-12, Tecfidera) approved for use by the NHS in Scotland
Primary Progressive MS evolving from Radiologically Isolated Syndrome.
Use of rituximab in multiple sclerosis: current progress and future perspectives.
Pages
« first
‹ previous
…
45
46
47
48
49
50
51
52
53
…
next ›
last »